Program
Oxymetazoline
Also written as “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, “Oxymetazoline Hydrochloride” and “Oxymetazoline HCL Cream 1.0%”.
Its studies are mostly in Rosacea · Erythema · Fecal Incontinence · Rhinitis, Allergic · Nasal Obstruction, led by 10 companies.
Drug pageOxymetazoline: every studyMany companies study it; this page follows only the 16 they lead. All 44 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 60 open or running | phase 3since Mar 21, 2014 | Apr 13, 2012 | none ahead |
| RDD Pharmaits history only | 20 open or running | phase 2since Nov 17, 2014 | Nov 17, 2014 | none ahead |
| Aclaris Therapeuticsits history only | 10 open or running | phase 4since Dec 18, 2017 | Dec 18, 2017 | none ahead |
| Bayerits history only | 10 open or running | phase 2since May 6, 2026 | May 6, 2026 | none ahead |
| Eye Therapiesits history only | 10 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since May 30, 2014 | May 30, 2014 | none ahead |
| Padagisits history only | 10 open or running | phase 3since Nov 7, 2017 | Nov 7, 2017 | none ahead |
| Santen Pharmaceuticalits history only | 11 open or running | phase 3since Jul 3, 2024 | Jul 3, 2024 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 1since Nov 23, 2021 | Nov 23, 2021 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Apr 10, 2019 | Apr 10, 2019 | none ahead |
Also a collaborator on its studies: Quintiles, Ground Zero Pharmaceuticals, Rho and ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jan 10, 2011.
- Apr 13, 2012AbbVie’s first study: phase 1 study in RosaceaNew to AbbVieAbbVie · NCT01579084 · 64 enrolled · United States
- Nov 26, 2012Phase 2 study in RosaceaAbbVie · NCT01735201 · 357 enrolled · United States
- Mar 21, 2014Phase 3 study in ErythemaAbbVie · NCT02095158 · 440 enrolled · United States
- May 5, 20142 phase 3 studies in ErythemaAbbVie · NCT02132117, NCT02131636
- May 30, 2014Johnson & Johnson’s first study: phase 1 study in Rhinitis, AllergicNew to Johnson & JohnsonJohnson & Johnson · NCT02154334 · 47 enrolled · Germany
- Jul 21, 2014Phase 2 study in PresbyopiaAbbVie · NCT02197806 · 65 enrolled · United States
- Nov 17, 2014RDD Pharma’s first study: phase 2 study in Fecal IncontinenceNew to RDD PharmaRDD Pharma · NCT02299557 · 19 enrolled · Hungary
- Nov 7, 2017Padagis’s first study: phase 3 study in RosaceaNew to PadagisPadagis · NCT03352323 · 50 enrolled · United States
- Dec 18, 2017Aclaris Therapeutics’ first study: phase 4 study in RosaceaNew to Aclaris TherapeuticsAclaris Therapeutics · NCT03380390 · 46 enrolled · United States
- May 7, 2018Phase 1 study in Fecal IncontinenceRDD Pharma · NCT03529487 · 40 enrolled · United States
- Apr 10, 2019Teva Pharmaceutical Industries’ first study: phase 3 study in RosaceaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT03954444 · 1,105 enrolled · United States
- Nov 23, 2021Sun Pharmaceutical Industries’ first study: phase 1 study in BioequivalenceNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT05148689 · 82 enrolled · United States
- Jul 3, 2024Santen Pharmaceutical’s first study: phase 3 study in Acquired BlepharophimosisNew to Santen PharmaceuticalSanten Pharmaceutical · NCT06514612 · 234 planned · Czechia, France, Germany and more
- May 6, 2026Bayer’s first study: phase 2 study in Nasal ObstructionNew to BayerBayer · NCT07582328 · 120 enrolled · Canada
TargetBeta
“Adrenergic receptor alpha agonist”ChEMBL 37, by rule
Other programs on the same 6 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07582328Nasal Obstruction · Canada | 2 | Completed | Bayer | May 28, 2026 | 120 |
| NCT06514612Acquired Blepharophimosis · Czechia, France, Germany and more | 3 | Recruiting | Santen Pharmaceutical | Aug 1, 2026 | 234 |
| NCT05148689Bioequivalence · United States | 1 | Completed | Sun Pharmaceutical Industries | Mar 21, 2019 | 82 |
| NCT03954444Rosacea · United States | 3 | Completed | Teva Pharmaceutical Industries | Jan 7, 2020 | 1,105 |
| NCT03529487Fecal Incontinence · United States | 1 | UNKNOWN | RDD Pharma | Dec 1, 2023 | 40 |
| NCT03380390Rosacea · United States | 4 | Completed | Aclaris Therapeutics | Jun 15, 2018 | 46 |
| NCT03352323Rosacea · United States | 3 | Completed | Padagis | Dec 6, 2017 | 50 |
| NCT02299557Fecal Incontinence · Hungary | 2 | Completed | RDD Pharma | Jun 2015 | 19 |
| NCT02197806Presbyopia · United States | 2 | Completed | AbbVie | Oct 2014 | 65 |
| NCT02154334Rhinitis, Allergic · Germany | 1 | Completed | Johnson & Johnson | Oct 2014 | 47 |
| NCT02132117Erythema · United States | 3 | Completed | AbbVie | Apr 2015 | 445 |
| NCT02131636Erythema · United States | 3 | Completed | AbbVie | Nov 2014 | 440 |
| NCT02095158Erythema · United States | 3 | Completed | AbbVie | Aug 2015 | 440 |
| NCT01735201Rosacea · United States | 2 | Completed | AbbVie | May 2013 | 357 |
| NCT01579084Rosacea · United States | 1 | Completed | AbbVie | Jun 2012 | 64 |
| NCT01275105Conjunctivitis, Allergic · United States | 2 | Completed | Eye Therapies | Mar 2011 | 68 |
How it is read
Names in the registry
- “Oxymetazoline”, 3 entries
- “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, 2 entries
- “Oxymetazoline Hydrochloride”, 2 entries
- “Oxymetazoline HCL Cream 1.0%”, 2 entries
- “AGN-199201”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 5 studies
- Erythema, 3 studies
- Fecal Incontinence, 2 studies
- Rhinitis, Allergic, 2 studies
- Nasal Obstruction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.